New Nordic Healthbrands AB

As of June 30, 2026, New Nordic Healthbrands AB carries a market capitalization of 74.96M, placing it among publicly traded companies globally. Its enterprise value stands at 102.11M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, New Nordic Healthbrands AB has 6.20M shares outstanding.

As of June 30, 2026, New Nordic Healthbrands AB trades at a trailing price-to-earnings ratio of 8.71. The price-to-sales ratio is 0.13, and the price-to-book ratio stands at 0.69.

As of June 30, 2026, New Nordic Healthbrands AB trades at an EV/EBITDA multiple of 5.80 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 0.17 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 6.80 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. New Nordic Healthbrands AB trades at an EV/FCF ratio of 25.02, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 102.11M versus a market cap of 74.96M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, New Nordic Healthbrands AB maintains a current ratio of 1.50, meaning it holds 1.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 34.11, indicating elevated leverage, while an interest coverage ratio of 9.96 demonstrates adequate ability to service its debt obligations.

Over the twelve months ended June 30, 2026, New Nordic Healthbrands AB posted a return on equity (ROE) of 8.26, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 6.75 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 3.18, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 6.87, useful for judging operating efficiency across full business cycles. The company generates approximately 7.71M in revenue per employee across its workforce of 76.50, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.86 indicates how many times New Nordic Healthbrands AB sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, New Nordic Healthbrands AB recorded 4.69M in income tax expense. That works out to an effective tax rate of 35.28, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 13.30M, leaving 8.61M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, New Nordic Healthbrands AB's stock has declined approximately 22.57% over the past 52 weeks. The 50-day moving average sits at 17.65, while the 200-day moving average is 16.89.

Over the twelve months ended June 30, 2026, New Nordic Healthbrands AB generated 589.78M in revenue and converted that into 8.61M in net income, yielding earnings per share of 1.39. EBITDA reached 17.61M, while operating income came in at 15.01M.

As of June 30, 2026, New Nordic Healthbrands AB holds 9.91M in cash and equivalents against 37.06M in total debt, resulting in a net debt position of 27.15M. Total book value stands at 108.65M, with working capital of 90.16M providing operational flexibility.

New Nordic Healthbrands AB produced 6.44M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -3.50M in capital expenditures, free cash flow totaled 2.94M - equivalent to 0.47 per share.

Over the twelve months ended June 30, 2026, New Nordic Healthbrands AB posted a gross margin of 63.37, reflecting its pricing power and cost economics. The operating margin of 2.54 and net profit margin of 1.46 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield stands at 3.92, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 5.66, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to New Nordic Healthbrands AB shareholders.